CARLSBAD, Calif.; RESEARCH TRIANGLE PARK, NC --- Invitrogen, part of Life Technologies Corporation (NASDAQ: LIFE), today announced the appointment of Thomas Rushmore, a distinguished researcher in the areas of drug metabolism and pharmacogenomic technologies, as a research fellow for its hepatic biology business, also known as CellzDirect.
In this role, Dr. Rushmore will serve as a technical expert on the development of new in vitro drug development services, as well as new products related to the Company’s cryopreserved hepatocytes technology portfolio.
Robert Brainin, Vice-President and General Manager, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“We are grateful to have Dr. Rushmore as a member of our management team. With over 20 years experience at Merck, Tom provides a valuable perspective on our market. He understands the perspective of the bench scientist as well as the challenges currently facing the pharmaceutical industry in drug discovery and development."
A researcher and educator who has evaluated and created numerous in vitro methods, Dr. Rushmore has published more than 85 peer-reviewed articles and reviews in the areas of CYP450 induction, CYP450 inhibition, drug metabolism, metabolite production and pharmacogenomics. Between 1987 and 2008 Dr. Rushmore worked in varying capacities at Merck & Company, Merck Frosst and Merck Research Labs, most recently as a senior investigator for Merck’s drug metabolism and pharmacokinetics (DMPK) group. Currently, Dr. Rushmore is an adjunct professor of Pharmacology/Toxicology at the University of the Sciences in Philadelphia. Dr. Rushmore holds a Ph.D. in Biochemistry and Molecular Biology from Thomas Jefferson University.
Thomas Rushmore, Research Fellow, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“Having watched the extraordinary growth of CellzDirect, now part of Life Technologies, over the last several years, I am excited to be part of this team and contribute to further development of in vitro tools for the pharmaceutical and academic research markets."
Ed LeCluyse, Scientific Advisor, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“I’ve worked with Tom over the years in industry, and am excited to have a scientist of Tom’s stature join our team and bring value to researchers with new tools using hepatocytes and in vitro drug development tools."
About Invitrogen Products
Life Technologies’ Invitrogen brand represents the life-science industry’s most comprehensive portfolio of platform-independent, essential technologies for disease and drug research, bioproduction and diagnostics. Invitrogen products provide the broadest range of differentiated reagents, kits and bench-top devices for the dynamic research and application needs of scientists around the world. Through its Invitrogen and Applied Biosystems brand of optimized instrument systems and workflows, Life Technologies markets the most comprehensive portfolio of solutions for molecular and cell biology. Invitrogen and Applied Biosystems products are used in nearly every major laboratory in the world. For more information, please visit: http://www.invitrogen.com/everyday and www.appliedbiosystems.com.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference, please visit our website, www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe”, “plan”, “intend”, “anticipate”, “target”, “estimate”, “expect”, and the like, and/or future tense or conditional constructions (“will”, “may”, “could”, “should”, etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Copyright 2009. Life Technologies Corporation. All rights reserved. Invitrogen is a trademark of Life Technologies in the US and/or certain other countries.
Source: Life Technologies Corporation
In this role, Dr. Rushmore will serve as a technical expert on the development of new in vitro drug development services, as well as new products related to the Company’s cryopreserved hepatocytes technology portfolio.
Robert Brainin, Vice-President and General Manager, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“We are grateful to have Dr. Rushmore as a member of our management team. With over 20 years experience at Merck, Tom provides a valuable perspective on our market. He understands the perspective of the bench scientist as well as the challenges currently facing the pharmaceutical industry in drug discovery and development."
A researcher and educator who has evaluated and created numerous in vitro methods, Dr. Rushmore has published more than 85 peer-reviewed articles and reviews in the areas of CYP450 induction, CYP450 inhibition, drug metabolism, metabolite production and pharmacogenomics. Between 1987 and 2008 Dr. Rushmore worked in varying capacities at Merck & Company, Merck Frosst and Merck Research Labs, most recently as a senior investigator for Merck’s drug metabolism and pharmacokinetics (DMPK) group. Currently, Dr. Rushmore is an adjunct professor of Pharmacology/Toxicology at the University of the Sciences in Philadelphia. Dr. Rushmore holds a Ph.D. in Biochemistry and Molecular Biology from Thomas Jefferson University.
Thomas Rushmore, Research Fellow, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“Having watched the extraordinary growth of CellzDirect, now part of Life Technologies, over the last several years, I am excited to be part of this team and contribute to further development of in vitro tools for the pharmaceutical and academic research markets."
Ed LeCluyse, Scientific Advisor, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies
“I’ve worked with Tom over the years in industry, and am excited to have a scientist of Tom’s stature join our team and bring value to researchers with new tools using hepatocytes and in vitro drug development tools."
About Invitrogen Products
Life Technologies’ Invitrogen brand represents the life-science industry’s most comprehensive portfolio of platform-independent, essential technologies for disease and drug research, bioproduction and diagnostics. Invitrogen products provide the broadest range of differentiated reagents, kits and bench-top devices for the dynamic research and application needs of scientists around the world. Through its Invitrogen and Applied Biosystems brand of optimized instrument systems and workflows, Life Technologies markets the most comprehensive portfolio of solutions for molecular and cell biology. Invitrogen and Applied Biosystems products are used in nearly every major laboratory in the world. For more information, please visit: http://www.invitrogen.com/everyday and www.appliedbiosystems.com.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference, please visit our website, www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe”, “plan”, “intend”, “anticipate”, “target”, “estimate”, “expect”, and the like, and/or future tense or conditional constructions (“will”, “may”, “could”, “should”, etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Copyright 2009. Life Technologies Corporation. All rights reserved. Invitrogen is a trademark of Life Technologies in the US and/or certain other countries.
Source: Life Technologies Corporation
